- Home
- MCR vs VNDA Comparison
MCR vs VNDA Comparison
Compare MCR & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- VNDA
- Stock Information
- Founded
- MCR 1989
- VNDA 2002
- Country
- MCR United States
- VNDA United States
- Employees
- MCR N/A
- VNDA N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- MCR Finance
- VNDA Health Care
- Exchange
- MCR Nasdaq
- VNDA Nasdaq
- Market Cap
- MCR 266.0M
- VNDA 237.9M
- IPO Year
- MCR N/A
- VNDA 2006
- Fundamental
- Price
- MCR $6.01
- VNDA $4.41
- Analyst Decision
- MCR
- VNDA Strong Buy
- Analyst Count
- MCR 0
- VNDA 2
- Target Price
- MCR N/A
- VNDA $16.50
- AVG Volume (30 Days)
- MCR 66.7K
- VNDA 735.6K
- Earning Date
- MCR 01-01-0001
- VNDA 05-07-2025
- Dividend Yield
- MCR 8.52%
- VNDA N/A
- EPS Growth
- MCR N/A
- VNDA N/A
- EPS
- MCR 0.38
- VNDA N/A
- Revenue
- MCR N/A
- VNDA $198,772,000.00
- Revenue This Year
- MCR N/A
- VNDA $14.36
- Revenue Next Year
- MCR N/A
- VNDA $44.53
- P/E Ratio
- MCR $16.61
- VNDA N/A
- Revenue Growth
- MCR N/A
- VNDA 3.18
- 52 Week Low
- MCR $5.63
- VNDA $3.85
- 52 Week High
- MCR $6.70
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- MCR 38.98
- VNDA 48.13
- Support Level
- MCR $5.96
- VNDA $4.27
- Resistance Level
- MCR $6.07
- VNDA $4.46
- Average True Range (ATR)
- MCR 0.12
- VNDA 0.22
- MACD
- MCR -0.00
- VNDA 0.02
- Stochastic Oscillator
- MCR 56.13
- VNDA 83.58
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income. The fund invests the assets in debt instruments. It invests the assets in corporate bonds of U.S. and foreign issuers, U.S. Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S. and foreign issuers, and debt instruments of issuers located in emerging market countries.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.